2018
Impact of carboplatin hypersensitivity and desensitization on patients with recurrent ovarian cancer
Altwerger G, Florsheim EB, Menderes G, Black J, Schwab C, Gressel GM, Nelson WK, Carusillo N, Passante T, Huang G, Litkouhi B, Azodi M, Silasi DA, Santin A, Schwartz PE, Ratner ES. Impact of carboplatin hypersensitivity and desensitization on patients with recurrent ovarian cancer. Journal Of Cancer Research And Clinical Oncology 2018, 144: 2449-2456. PMID: 30255380, DOI: 10.1007/s00432-018-2753-y.Peer-Reviewed Original ResearchConceptsCarboplatin hypersensitivityCarboplatin desensitizationHypersensitive patientsOverall survivalRisk factorsOvarian cancerTwo-sided Fisher exactAdvanced stage ovarian cancerInfusion of carboplatinRecurrent ovarian cancerIndependent risk factorLonger overall survivalStage ovarian cancerOvarian cancer patientsLong-term treatmentNew risk factorsHigher likelihoodTwo-sided p valueT-testStudent's t-testDesignRetrospective studyGermline BRCA1/2Improved OSLonger OSDesensitization protocolA novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma
Han C, Bellone S, Siegel ER, Altwerger G, Menderes G, Bonazzoli E, Egawa-Takata T, Pettinella F, Bianchi A, Riccio F, Zammataro L, Yadav G, Marto JA, Penet MF, Levine DA, Drapkin R, Patel A, Litkouhi B, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin AD. A novel multiple biomarker panel for the early detection of high-grade serous ovarian carcinoma. Gynecologic Oncology 2018, 149: 585-591. PMID: 29572027, PMCID: PMC5986604, DOI: 10.1016/j.ygyno.2018.03.050.Peer-Reviewed Original ResearchConceptsHigh-grade serous ovarian carcinomaSerous ovarian carcinomaIL-6Ovarian cancerOvarian carcinomaE-cadHigh-grade serous ovarian adenocarcinomaEarly-stage ovarian cancerROC analysisEarly detectionMajority of patientsLethal gynecologic malignancyStage ovarian cancerOvarian cancer patientsBenign gynecologic pathologyNon-cancer controlsSerous ovarian adenocarcinomaEffective cancer screeningSerous ovarian cancerMultiple biomarker panelsFour-marker panelHigh differential gene expressionGynecologic malignanciesCA 125IL-1ra
2017
Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted?
McGee J, Giannakeas V, Karlan B, Lubinski J, Gronwald J, Rosen B, McLaughlin J, Risch H, Sun P, Foulkes WD, Neuhausen SL, Kotsopoulos J, Narod SA, Group O. Risk of breast cancer after a diagnosis of ovarian cancer in BRCA mutation carriers: Is preventive mastectomy warranted? Gynecologic Oncology 2017, 145: 346-351. PMID: 28314588, DOI: 10.1016/j.ygyno.2017.02.032.Peer-Reviewed Original ResearchConceptsBRCA mutation carriersOvarian cancer patientsOvarian cancerBreast cancerMutation carriersPreventive mastectomyCancer patientsActuarial riskStage III/IV ovarian cancerUnaffected BRCA mutation carriersEarly-stage ovarian cancerBreast cancer incidenceStage ovarian cancerMutation-carrying patientsProportional hazards modelCause of mortalityImpact of mastectomyOvarian cancer diagnosisProbability of deathBreast surveillanceCause mortalityAnnual mortality rateClinical benefitBreast surgeryInternational registry
2012
Neoadjuvant chemotherapy (NACT) is an effective way of managing elderly women with advanced stage ovarian cancer (FIGO Stage IIIC and IV)
Glasgow MA, Yu H, Rutherford TJ, Azodi M, Silasi D, Santin AD, Schwartz PE. Neoadjuvant chemotherapy (NACT) is an effective way of managing elderly women with advanced stage ovarian cancer (FIGO Stage IIIC and IV). Journal Of Surgical Oncology 2012, 107: 195-200. PMID: 22648987, DOI: 10.1002/jso.23171.Peer-Reviewed Original ResearchMeSH KeywordsAge FactorsAgedAged, 80 and overAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsCarboplatinCarcinoma, Ovarian EpithelialChemotherapy, AdjuvantCohort StudiesDrug Administration ScheduleFemaleHumansNeoadjuvant TherapyNeoplasm StagingNeoplasms, Glandular and EpithelialOvarian NeoplasmsPaclitaxelRetrospective StudiesSurvival AnalysisTreatment OutcomeConceptsEpithelial ovarian cancerAdvanced stage ovarian cancerUpfront cytoreductive surgeryNeoadjuvant chemotherapyStage ovarian cancerCytoreductive surgeryOvarian cancerNACT patientsAge 70Stage IV epithelial ovarian cancerAdvanced epithelial ovarian cancerImproved progression-free survivalRetrospective cohort studyShorter ICU stayStage IV diseaseProgression-free survivalLess blood lossSmall bowel resectionOverall survival analysisICU staySame chemotherapyUpfront surgeryMacroscopic diseasePerioperative morbidityStage IIIC
2009
Peritoneal tuberculosis with elevated serum Ca-125 level mimicking advanced stage ovarian cancer: a case report
Tan O, Luchansky E, Rosenman S, Pua T, Azodi M. Peritoneal tuberculosis with elevated serum Ca-125 level mimicking advanced stage ovarian cancer: a case report. Archives Of Gynecology And Obstetrics 2009, 280: 333-335. PMID: 19184073, DOI: 10.1007/s00404-009-0946-y.Peer-Reviewed Original ResearchConceptsSerum CA-125 levelsCA-125 levelsPeritoneal tuberculosisCA 125Elevated serum CA 125 levelsAdvanced stage ovarian cancerElevated serum CA 125Unnecessary extensive surgerySerum CA 125Resolution of symptomsFrozen section evaluationStage ovarian cancerAcid-fast stainOmental cakingAbdominal distentionExtrapulmonary diseaseNight sweatsDiagnostic laparoscopyCommon presentationExtensive surgeryMultiple granulomasPhysical examinationRadiologic studiesCase reportOvarian cancerExpression and prognostic significance of kallikrein-related peptidase 8 protein levels in advanced ovarian cancer by using automated quantitative analysis
Kountourakis P, Psyrri A, Scorilas A, Markakis S, Kowalski D, Camp RL, Diamandis EP, Dimopoulos MA. Expression and prognostic significance of kallikrein-related peptidase 8 protein levels in advanced ovarian cancer by using automated quantitative analysis. Thrombosis And Haemostasis 2009, 101: 541-546. PMID: 19277417, DOI: 10.1160/th08-01-0052.Peer-Reviewed Original ResearchConceptsProgression-free survivalOvarian cancerPrognostic significanceSurvival analysisFive-year overall survivalPlatinum-paclitaxel combination chemotherapyYear progression-free survivalAdvanced stage ovarian cancerAdvanced ovarian cancerStage ovarian cancerMultivariate survival analysisUnivariate survival analysisImportant prognostic biomarkerSerine protease enzyme familyExpression levelsSignificant correlationWarrants further investigationProtein expression levelsKLK8 expressionClinical responseOverall survivalSurgical debulkingCombination chemotherapyPrognostic valueResidual disease
2008
Prognostic value of kallikrein‐related peptidase 6 protein expression levels in advanced ovarian cancer evaluated by automated quantitative analysis (AQUA)
Kountourakis P, Psyrri A, Scorilas A, Camp R, Markakis S, Kowalski D, Diamandis EP, Dimopoulos MA. Prognostic value of kallikrein‐related peptidase 6 protein expression levels in advanced ovarian cancer evaluated by automated quantitative analysis (AQUA). Cancer Science 2008, 99: 2224-2229. PMID: 18957059, PMCID: PMC11159123, DOI: 10.1111/j.1349-7006.2008.00942.x.Peer-Reviewed Original ResearchConceptsOvarian cancerOverall survivalPrognostic valueKLK6 expressionSurvival analysisPlatinum-paclitaxel combination chemotherapyAdvanced stage ovarian cancerAdvanced ovarian cancerProgression-free survivalProtein expressionStage ovarian cancerInferior patient outcomesUnivariate survival analysisMultivariate survival analysisImportant prognostic biomarkerSerine protease enzyme familyExpression levelsProtein expression levelsSurgical debulkingCombination chemotherapyPatient outcomesPrognostic biomarkerPrognostic variablesSufficient tissueTherapeutic target
2007
Evaluation of the prognostic significance of human kallikrein 8 protein expression levels in advanced ovarian cancer by using automated quantitative protein analysis
Kountourakis P, Psyrri A, Scorilas A, Markakis S, Kowalski D, Camp R, Diamandis E, Dimopoulos M. Evaluation of the prognostic significance of human kallikrein 8 protein expression levels in advanced ovarian cancer by using automated quantitative protein analysis. Journal Of Clinical Oncology 2007, 25: 5581-5581. DOI: 10.1200/jco.2007.25.18_suppl.5581.Peer-Reviewed Original ResearchOvarian cancerProtein expression levelsPrognostic significanceSurvival analysisPlatinum-paclitaxel combination chemotherapyYear progression-free survivalAdvanced stage ovarian cancerExpression levelsProgression-free survivalAdvanced ovarian cancerAdverse prognostic factorDisease-free survivalStage ovarian cancerUnivariate survival analysisMultivariate survival analysisKallikrein-8Important prognostic biomarkerSerine protease enzyme familyFree survivalSurgical debulkingCombination chemotherapyPrognostic factorsPrognostic valueResidual diseaseClinicopathological variablesAnalysis of p53 protein expression levels on ovarian cancer tissue microarray using automated quantitative analysis elucidates prognostic patient subsets
Psyrri A, Kountourakis P, Yu Z, Papadimitriou C, Markakis S, Camp R, Economopoulos T, Dimopoulos M. Analysis of p53 protein expression levels on ovarian cancer tissue microarray using automated quantitative analysis elucidates prognostic patient subsets. Annals Of Oncology 2007, 18: 709-715. PMID: 17220511, DOI: 10.1093/annonc/mdl479.Peer-Reviewed Original ResearchConceptsDisease-free survivalOverall survivalP53 protein levelsP53 expression levelsPrognostic valueOvarian cancerBetter outcomesProtein levelsAdvanced stage ovarian cancerExpression levelsP53 protein expression levelsOvarian cancer tissue microarrayStage ovarian cancerOvarian cancer prognosisP53 levelsCancer tissue microarrayValuable prognostic markerP53 protein expressionSignificant predictor variablesProtein expression levelsObstetrics stageFIGO stagePatient subsetsMultivariable analysisPrognostic marker
2005
Subcellular Localization and Protein Levels of Cyclin-Dependent Kinase Inhibitor p27 Independently Predict for Survival in Epithelial Ovarian Cancer
Psyrri A, Bamias A, Yu Z, Weinberger PM, Kassar M, Markakis S, Kowalski D, Efstathiou E, Camp RL, Rimm DL, Dimopoulos MA. Subcellular Localization and Protein Levels of Cyclin-Dependent Kinase Inhibitor p27 Independently Predict for Survival in Epithelial Ovarian Cancer. Clinical Cancer Research 2005, 11: 8384-8390. PMID: 16322299, DOI: 10.1158/1078-0432.ccr-05-1270.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overBiomarkers, TumorCell DifferentiationCohort StudiesCombined Modality TherapyCyclin-Dependent Kinase Inhibitor p27Cystadenocarcinoma, SerousFemaleHumansMiddle AgedNeoplasm StagingNeoplasms, Glandular and EpithelialOvarian NeoplasmsPrognosisSubcellular FractionsSurvival RateTissue Array AnalysisConceptsNuclear p27 expressionOvarian cancerP27 expression levelsOverall survivalP27 expressionPlatinum-paclitaxel combination chemotherapyAdvanced stage ovarian cancerDisease-free survivalSignificant prognostic factorsStage ovarian cancerEpithelial ovarian cancerValuable prognostic biomarkerExpression levelsP27 protein expressionCyclin-dependent kinase inhibitor p27Mean followSurgical debulkingCombination chemotherapyPrognostic factorsMultivariable analysisPrognostic valueImmunohistochemical assessmentPrognostic biomarkerPrognostic variablesImmunofluorescence-based method
2004
Immunological treatment of ovarian cancer
Cannon MJ, Santin AD, O'Brien TJ. Immunological treatment of ovarian cancer. Current Opinion In Obstetrics & Gynecology 2004, 16: 87-92. PMID: 15128013, DOI: 10.1097/00001703-200402000-00015.Peer-Reviewed Original ResearchConceptsImmunological treatmentOvarian cancerAntibody responseClinical trialsAntigen-specific helper T lymphocytesAdvanced stage ovarian cancerHuman anti-mouse antibody responseAnti-mouse antibody responseImportant target antigenNovel immunological treatmentsDendritic cell vaccinationNovel immunotherapeutic strategiesT cell immunityT lymphocyte responsesStage ovarian cancerHelper T lymphocytesRecent clinical trialsOvarian tumor antigenElicit antibody responsesMouse monoclonal antibodyEvasion of immunityTime of treatmentCell vaccinationRecurrent diseaseImmunotherapeutic strategies
2001
Early stage ovarian cancer: the Italian contribution to clinical research. An update
Favalli G, Odicino F, TORRI V, Pecorelli S. Early stage ovarian cancer: the Italian contribution to clinical research. An update. International Journal Of Gynecological Cancer 2001, 11: 12-19. DOI: 10.1136/ijgc-00009577-200107001-00004.Peer-Reviewed Original ResearchEarly ovarian cancerStage ovarian cancerOvarian cancerRandomized trialsStage I ovarian cancer patientsProspective multicentre randomized trialEarly stage ovarian cancerSchedule of cisplatinStage IC patientsStages IA-IIANode positivity ratePlatinum-based chemotherapyEpithelial ovarian cancerMulticentre randomized trialMainstays of treatmentImpact of chemotherapyProbability of cureHeterogeneity of patientsItalian institutionsClinical researchUnilateral oophorectomyConservative surgeryOverall survivalAdjuvant chemotherapyPositive nodes
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply